Pharmacy Advisor program proving that it fills gaps in care
WHAT IT MEANS AND WHY IT’S IMPORTANT — The results of CVS Caremark’s study, which found that its Pharmacy Advisor program increased medication adherence rates and physician initiation of prescriptions, is important as it further underscores the benefits of the program, and those benefits are bound to becomes even greater as the retailer gears up for the next generation of the clinical program.
(THE NEWS: CVS Caremark study: Pharmacy Advisor improved diabetes Rx initiation, adherence rates. For the full story, click here)
The research showed that contacts by pharmacists with the patients and their doctors increased therapy initiation rates by as much as 39% for the full sample and an even higher 68% for the group counseled at retail stores, and increased medication adherence rates by 2.1%. The researchers noted that face-to-face interventions by retail store pharmacists resulted in increasing adherence rates by 3.9%.
The integrated pharmacy-based program featured counseling by pharmacists at 12 retail stores near the manufacturing client’s headquarters, and counseling through a pharmacist call center for those identified as having diabetes. CVS Caremark launched Pharmacy Advisor for diabetes in 2009 because the cost and prevalence of that disease continues to rise. The American Diabetes Association estimates the cost of the disease to the U.S. in 2007 at $174 billion.
During the company’s 2011 Analyst Day in late December, Troyen Brennan, EVP and chief medical officer, noted that, “As we rolled out the Pharmacy Advisor program last year at this time we thought that perhaps clients with one to three million members would be interested, it was a new program and all. But on April 1 … we started with nearly 12 members and have been tracking results since.”
Brennan said that within that population of 12 million members there are roughly 700,000 diabetics, and in just over six months of enrollment it had delivered more than one million interventions — the overwhelming number of them at the retail level. That has led to 470,000 communications about gaps in care and more than 110,000 changes in medications. Those are impressive numbers.
Now, the company is looking to expand the program with the launch of Pharmacy Advisor 3.0, which will include additional disease states and additional clinical intervention opportunities. The program clearly marks one more way in which CVS Caremark is helping to drive adherence and lower costs.
NCR introduces cloud-based POS system for independent retailers
DULUTH, Ga. — NCR announced Monday the introduction of a point-of-sale system that will allow independent retailers to manage transactions, track sales and inventory, process credit cards and market to customers on both touchscreen terminals and Apple mobile devices.
The system is a cloud-based platform that NCR said would give independent retailers a multichannel "sell anywhere" capability.
"This new solution makes big-box retail technology accessible for all and enables merchants to focus on their business, not on managing technology," NCR VP specialty retail Christian Nahas said. "We are passionate about helping small businesses run and scale their business, connect with customers across channels and sell anywhere. We are actively talking to all types of organizations who sell to small businesses, and the feedback has been overwhelming: They can’t wait to take this product to their customers."
The platform is scheduled to become widely available in early spring.
FDA submits recommendations for Generic Drug User Fee Act
WASHINGTON — The Food and Drug Administration has finished and sent to Congress its recommendations for a proposed Generic Drug User Fee Act, drawing praise from the generic drug industry.
GDUFA calls for the generic industry to pay $299 million per year for five years, in addition to what Congress gives the FDA. The money would come in the form of user fees for companies that submit regulatory approval applications to the agency for review.
Over the years, the agency has racked up a backlog of more than 1,000 generic drug approval applications and, according to the Generic Pharmaceutical Association, it takes 31 months for the FDA to review an application submitted electronically. Supporters, such as the GPhA, hope that GDUFA will help reduce the wait time to 10 months and eliminate the backlog by the end of fiscal year 2017.
"This is an important landmark that could not have been achieved without the extraordinary efforts of the FDA, my colleagues in the generic industry and all other stakeholders," GPhA president and CEO Ralph Neas said. "We now look forward to working with members of Congress in the weeks and months ahead to ensure that the final program is one that expedites access to low-cost, high-quality generic drugs for Americans and further safeguards the quality and accessibility of our nation’s drug supply."